- WACKER is investing a mid-double-digit million-euro amount in its Amsterdam site.
- A new 1,500-liter fermentation line will replace the existing one after a transition period.
- Cleanroom structures in the 270-liter fermentation line will be renovated and upgraded.
- The upgrades will support production of pDNA and mRNA-based vaccines.
Investment Overview
WACKER is investing a mid-double-digit million-euro amount in its Amsterdam site to enhance its production facilities for biologics, live microbial products (LMPs), and vaccines. This investment includes the construction of a new 1,500-liter fermentation line and the renovation of cleanroom structures in the 270-liter fermentation line.
Facility Upgrades
The new 1,500-liter fermentation line will eventually replace the existing one after a transition period. Additionally, the cleanroom structures in the 270-liter fermentation line will be gutted, renovated, and equipped with state-of-the-art equipment, including new utility supplies like water for injection. These upgrades will enable the production of new classes of actives, such as pDNA and mRNA-based vaccines.
Strategic Importance
The investment is a strategic move to support WACKER's growth in the fast-growing pharmaceutical market. The new structures and equipment will help meet customer demand and strengthen WACKER's position as a leading contract manufacturer in microbial production of biologics.
Site Capabilities
WACKER's Amsterdam site, acquired in 2018, doubled the company's biologics capacity and expanded its portfolio to include vaccines and live microbial products. The site currently has two fermentation lines with capacities of 1,500 and 270 liters, respectively, and also offers single-use fermenters with a capacity of 250 liters. The facility includes a fill-and-finish unit for complete pharmaceutical manufacturing from active agents to filled products.
